COMPASS Trial Visual Abstract: Rivaroxaban plus aspirin in stable cardiovascular disease
Does adding rivaroxaban to aspirin therapy in patients with stable cardiovascular disease affect outcomes? This was the question answered by the large-sized multi-center COMPASS trial that evaluated the combination of rivaroxaban and aspirin and compared it with aspirin alone. The results showed moderate improvement in outcomes at the expense of increased bleeding risk.
[TheChamp-Sharing style="background-color:#FFFFFF;"]Want to read more posts?